Last reviewed · How we verify
Flonoltinib Maleate Tablets
At a glance
| Generic name | Flonoltinib Maleate Tablets |
|---|---|
| Also known as | 25mg Flonoltinib Maleate Tablets, 50mg Flonoltinib Maleate Tablets, 100mg Flonoltinib Maleate Tablets, 150mg Flonoltinib Maleate Tablets, 200mg Flonoltinib Maleate Tablets |
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (PHASE2)
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (PHASE3)
- A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (PHASE2)
- Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative (PHASE1, PHASE2)
- A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets (PHASE1)
- A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects (PHASE1)
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis (PHASE2)
- Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: